In what was a fait accompli after a failed outcomes study for Merck's (NYSE:MRK) cholesterol drug Tredaptive, the big pharma giant just announced it was suspending sales of the drug. Motley Fool health-care analyst David Williamson explains the embarrassing situation and what this means for investors.

 

 

David Williamson owns shares of Amarin plc (ADR). Follow him on Twitter @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.